임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
35건 표시
- 1/2상모집 중단 (진행 중)· Melanoma MetastaticDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· MSI-H/dMMR Gastroesophageal-junction CancerA Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Bladder CancerA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
리드: 머크(MSD) · 협력: 모더나
- 1/2상모집 중단 (진행 중)· Glioblastoma MultiformeT Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Solid TumorsBI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaA Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Esophageal CancerOral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Advanced or Metastatic Solid TumorsA Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· MelanomaA Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Renal Cell CarcinomaA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Platinum-refractory Ovarian CarcinomaOncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Neurofibromatosis Type 1Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
리드: 아스트라제네카 · 협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
리드: 일라이 릴리 · 협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Carcinoma, Renal CellSubstudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Carcinoma, Renal CellSubstudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Endometrial CarcinomaGYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Solid Tumor, AdultStudy to Evaluate D-1553 in Subjects With Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Solid Tumor, AdultNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Solid Tumor, AdultStudy Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Non Small Cell Lung CancerUCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Locally Recurrent CancerBevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Ovarian Cancer RecurrentSystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Unresectable or Metastatic Melanoma or Advanced Solid TumorsA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Breast CancerHer2-BATS and Pembrolizumab in Metastatic Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Melanoma and Other Malignant Neoplasms of SkinStudy of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
협력: GSK, 머크(MSD)
- 1/2상모집 중단 (진행 중)· Chronic Lymphocytic LeukemiaStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Lymphoma, B-CellA Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Castration-Resistant Prostate CancerStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Lung CancerPembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Triple Negative Breast CancerStandard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungMK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.